Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 76.98B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 17.91 |
| Forward PE | 6.85 |
| Dividend | 2.22 (5.86%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 4,682 |
| Average Volume | 4,041 |
| Open | 38.80 |
| Previous Close | 38.81 |
| Day's Range | 37.90 - 39.12 |
| 52-Week Range | 37.01 - 58.79 |
| Beta | 0.34 |
| RSI | 41.99 |
| Earnings Date | Oct 30, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers Squibb: Value Emerges From Distress
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal
Bristol-Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.
Bristol Myers Squibb to buy Orbital Therapeutics for $1.5B in cash
Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives
BMS and NCPA to address cardiovascular disease and enhance patient care coordination with specialized training in rural Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri pharmaciesOrig...
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
BMY November 28th Options Begin Trading
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the November 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the B...
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO
Billionaires Are Piling Into United Health Group and These 2 Stocks
UnitedHealth Group (NYSE:UNH), Bristol-Myers Squibb (NYSE:BMY) and Fiserv (NYSE:FI) have been getting plenty of attention from big name investors. Every three months, the SEC’s 13F filings open a smal...
Price Over Earnings Overview: Bristol-Myers Squibb
In the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) is trading at $45.73, after a 3.58% decrease. Over the past month, the stock decreased by 2.06% , and in the past year, by 15.25% . With ...
Bristol Myers Alzheimer's Drug Earns FDA Fast Track
Bristol Myers Alzheimer's Drug Earns FDA Fast Track
Bristol Myers Alzheimer's Drug Earns FDA Fast Track(EDIT)
Bristol Myers Alzheimer's Drug Earns FDA Fast Track(EDIT)
Chinese healthcare, biotech firms flock to Hong Kong for IPOs
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in th...
Bristol Myers Squibb (BMY) Gains FDA Fast Track for Alzheimer's Drug
Bristol Myers Squibb (BMY) Gains FDA Fast Track for Alzheimer's Drug
Bristol Myers Squibb antibody candidate for Alzheimer's granted Fast Track status
Ex-Dividend Reminder: Quest Diagnostics, Bristol Myers Squibb and Globe Life
Looking at the universe of stocks we cover at Dividend Channel, on 10/3/25, Quest Diagnostics, Inc. (Symbol: DGX), Bristol Myers Squibb Co. (Symbol: BMY), and Globe Life Inc (Symbol: GL) will all trad...
Bristol Myers (BMY) Receives Fast Track Status for Alzheimer's Treatment
Bristol Myers (BMY) Receives Fast Track Status for Alzheimer's Treatment
Bristol Myers Squibb Says FDA Grants Fast Track Status To BMS-986446 For Alzheimer's Treatment
(RTTNews) - Bristol Myers Squibb (BMY) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule...
Bristol Myers Squibb (BMY) Joins Consortium for AI Drug Discovery
Bristol Myers Squibb (BMY) Joins Consortium for AI Drug Discovery
Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden
The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.